Comparative Pharmacoeconomic Study of Proton Pump Inhibitors in Gastritis Treatment Using Cost Minimization Approach
- Reny Anggriany Hakim Institut Teknologi Kesehatan dan Sains Muhammadiyah Sidrap, Sidrap, Indonesia
- Shabran Hadiq Institut Teknologi Kesehatan dan Sains Muhammadiyah Sidrap, Sidrap, Indonesia
- Raudhatul Jannah Institut Teknologi Kesehatan dan Sains Muhammadiyah Sidrap, Sidrap, Indonesia
-
Sri Umi
*
Institut Teknologi Kesehatan dan Sains Muhammadiyah Sidrap, Sidrap,
Indonesia
(*) Corresponding Author
Abstract
Gastritis is an inflammatory condition of the gastric mucosa with varying degrees of severity, ranging from mild asymptomatic cases to more severe forms associated with significant morbidity. The condition may be influenced by multiple factors, including dietary habits that stimulate gastric acid secretion, irregular eating patterns, infections, psychological stress, alcohol consumption, and the use of certain medications such as nonsteroidal anti-inflammatory drugs and corticosteroids. Cost Minimization Analysis (CMA) is a pharmacoeconomic approach applied to compare therapeutic alternatives that have equivalent clinical effectiveness by identifying the option with the lowest direct medical cost. Meanwhile, studies examining real-world cost efficiency at the level of primary care services or private community pharmacies remain relatively limited and underreported. Therefore, this study aims to analyze the cost of PPI use in gastritis patients at Fella Farma Pharmacy in 2023 using the Cost Minimization Analysis (CMA) approach. The results of this study are expected to determine PPI alternatives with the lowest therapy costs as a basis for decision-making in more efficient and rational pharmaceutical services. This study conceptualizes that the use of proton pump inhibitors, specifically omeprazole and lansoprazole, influences the total therapy costs incurred by patients. The choice of PPI is assumed to affect overall treatment expenses as reflected in retrospective medical record data from Fella Farma Pharmacy in 2023. This study used a quantitative research design with retrospective data collection using medical records obtained from Fella Farma Pharmacy for the year 2023.A sample of 52 patients who met the inclusion and exclusion criteria at the Fella Farma Clinical Pharmacy in 2023. The data obtained were then analyzed for minimum costs to determine the lowest cost of treatment between Omeprazole (patent brand x) and Lansoprazole (patent brand y). The results of the study showed that the use of Proton Pump Inhibitor (PPI) drugs that had the lowest cost was omeprazole with an average total cost of IDR 351,000/patient compared to lansoprazole with an average total cost of IDR 514,000/patient.
Downloads
References
Abdelwahab Ahmed, & John O. Clarke. (2023). Proton Pump Inhibitors (PPI) 2023, May 1. StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK557385/
Akram, M., Mahmood, A., Umaru, I. J., Hasan, M. K., Abdulghafoor, H. A., Khan, F. S., Ozdemir, F. A., Solowski, G., Ali, J. Ben, & Al-Musawi, J. M. (2025). African Journal of Medicine, Surgery and Public Health Research. 2(2), 302–306. Akram, M., Mahmood, A., Umaru, I. J., Hasan, M. K., Abdulghafoor, H. A., Khan, F. S., Ozdemir, F. A., Solowski, G., Ali, J. Ben, & Al-Musawi, J. M. (2025). African Journal of Medicine, Surgery and Public Health Research. 2(2), 302–306.
Amalia, A., & Suardiana, I. K. (2025). The Role Of Pharmacoeconomics In Determining Treatment Selection In Indonesia : A Scoping Review. Journal Pharmaceutical Science and Application, 7(2), 40–50. https://doi.org/https://doi.org/10.24843/JPSA.2025.v07.i01.p05 effective
Artini, B., Prasetyo, W., & Lestari, M. P. (2022). Hubungan Pola Makan dan Stress terhadap Penyakit Gastritis: A Literature Review. Nursing Sciences Journal, 6(1), 13–22.
Azer SA, Awosika AO, A. H. (2024). Gastritis. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK544250/%0A
Faustina, C., Angellika, V., Rahmadani, A., Dorothea, R., Adiputra, R. fajar, & Maritska, Z. (2022). Potential of Anti-Secretory and Cytoprotective Effect from Azadiradione as GERD Ulcer Preventio. Sriwijaya Journal of Medicine, 5(2), 82–89. https://doi.org/10.32539/SJM.v5i2.144
Ferry, & Wijonarko. (2022). Pencegahan dan Penatalaksanaan Gastritis di Posyandu Lestari II di Kelurahan Tanjung Raya Kota Bandar Lampung. 1(1), 35–41.
Ho, C. W. W., & Chiou, F. K. (2023). Gastritis and Gastropathy : Perspectives From the Endoscopist. Digestive Medicine Research, 6(14), 1–4. https://doi.org/10.21037/dmr-22-77
Hutahaean, A. V, Citraningtyas, G., & Wewengkang, D. S. (2019). Analisis Efektivitas Biaya Pada Pasien Gastritis Rawat Inap Di Rumah Sakit Bhayangkara Manado. PHARMACON Jurnal Ilmiah Farmasi, 8(4), 767–773.
Islami, B. C., & Rahmaniar, R. (2025). Cost Minimization Analysis Penggunaan Antihipertensi Candesartan Dibandingkan Amlodipin pada Pasien Jkn Rawat Jalan di Rumah Sakit Roemani Muhammadiyah Semarang. Jurnal Pharmacopoeia, 4(2), 48–57. https://doi.org/10.33088/jp.v4i2.1008
Kang, S. J., Kim, J. G., Moon, H. S., Kook, M., Lee, J. Y., Bang, C. S., Tae, C. H., & Gong, E. J. (2023). Clinical Practice Guideline for Gastritis in Korea. Journal Korean Med Sci, 38(13), 1–25. https://doi.org/10.3346/jkms.2023.38.e115
Kuna, M. R., Sofiah, S. A., Adhi Wardhana Amrullah, Rakanita, Y., Washliaty Sirajuddin, Uneputty, J. P., Hakim, R. A., Hadiq, S., Handayani, M., Sandrawati, Rochmah, N. N., & Mahardika, M. P. (2024). Farmakoekonomi (H. Akbar (ed.)). Penamuda Media.
N, V., & B, F. M. (2003). Direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease. Aliment Pharmacol Ther, 18(6), 559-568. https://doi.org/10.1046/j.1365-2036.2003.01756.x.
Pratiwi, Y., & Azzahra, M. K. (2022). Analisis Efektivitas Biaya Berdasarkan Nilai Acer Penggunaan Proton Pump Inhibitor Pada Pasien Dispepsia Di Bangsal Rawat Inap RSUD RA Kartini Jepara. Cendekia Journal of Pharmacy, 6(1), 89–101.
Sari, P. N., Retno, E. K., Sari, M., Wadhana, M. A., & Biaya, E. (2024). Analisis Efektivitas Biaya Penggunaan Omeprazole dan Lansoprazole pada Pasien Gastritis di Instalasi Rawat Inap Rumah Sakit Pertamina Balikpapan. Prosiding Seminar SAFANA 2024, 35–42.
Serikbayeva, E., Suyunov, N., Makhatov, B., Atimtaikyzy, A., Ibragimova, A., & Abdullaeva, M. (2025). Pharmacoeconomic Analysis Of Medicines Used For Bronchial Asthma In Children In Kazakhstan. 29(1), 20–29. https://doi.org/10.34763/jmotherandchild.20252901.d-24-00046
Syari, D. M., & Sari, H. (2021). Evaluasi Penggunaan Obat Proton-Pump Inhibitor (PPI) pada Pasien Rawat Jalan di Rumah Sakit Imelda Medan. Jurnal Ilmiah Farmasi Imelda, 5(1), 1–4. https://jurnal.uimedan.ac.id/index.php/JURNALFARMASI%0A?
Tonin, F. S., Aznar-lou, I., Pontinha, V. M., Pontarolo, R., & Fernandez-llimos, F. (2021). Principles of pharmacoeconomic analysis : the case of pharmacist-led interventions. Pharmacy Practice, 19(1), 1–10. https://doi.org/https://doi.org/10.18549/PharmPract.2021.1.2302
Vg, M. P., Mcfarland, L. V, Thacker, H. P., Puri, R., & Lawate, P. S. (2024). Efficacy and Safety of Omeprazole for the Treatment of Acid Peptic Disorders : A Systematic Review and Meta-Analysis. International Journal of Clinical Practice, 2024, 1–13. https://doi.org/10.1155/2024/9990554
Wołowiec, Ł., Osiak-Gwiazdowska, J., Jaśniak, A., Michał Janiak, L. W., Magdalena Łukasiak, M. P., & Grześk, G. (2025). Pharmacodynamics, pharmacokinetics, interactions with other drugs, toxicity and clinical effectiveness of proton pump inhibitors. Frontiers in Pharmacology, July, 1–13. https://doi.org/10.3389/fphar.2025.1507812
Bila bermanfaat silahkan share artikel ini
Berikan Komentar Anda terhadap artikel Comparative Pharmacoeconomic Study of Proton Pump Inhibitors in Gastritis Treatment Using Cost Minimization Approach
Pages: 130-137
Copyright (c) 2025 Reny Anggriany Hakim
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under Creative Commons Attribution 4.0 International License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (Refer to The Effect of Open Access).
